SFB 1309 - Chemical Biology of Epigenetic Modifications






December 2, 2019 and February 3, 2020     

Vorlesung : " Wie entstehen Arzneimittel-Innovationen?" von Prof. Wolfgang Plischke

Nach Teilnahme an der Vorlesung findet am 12. Mai 2020 eine kostenlose Exkursion zu den Forschungseinrichtungen der Bayer AG statt. Teilnahmeliste wird zur Vorlesung ausliegen. Nähere Infos erteilt Frau Martina.Schuster@cup.uni-muenchen.de




December 6, 2019     Nikolaus-Symposium

Preliminary program

09:00-10:00   Anjana Rao (La Jolla, CA, USA)

10:00-11:00   Michaela Frye (DKFZ Heidelberg, Germany)

11:30-12:30   Petra Hajkova (Imperial College London, UK)

14:30-15:30   Dirk Schwarzer (Universität Tübingen, Germany)

15:30-16:30   Cynthia Burrows (University of Utah, UT, USA)

17:15-18:15   Juri Rappsilber (TU Berlin, Germany)


Ludwig-Maximilians-Universität München

BioSysM building, room K00.015

Butenandtstr. 1

81377 München














Headquarters of the SFB1309 will be the Institute for Chemical Epigenetics Munich ICEM
which is currently under construction.



The Collaborative Research Centre (SFB 1309) "Chemical Biology of Epigenetic Modifications" deals with the small chemical modifications of biomolecules. These epigenetic changes represent a second information level in the genetic makeup and play a crucial role in the regulation of various vital processes. The new CRC aims at explaining the chemical language of the modifications and at better understanding its origin and function. To do so, the scientists want to examine epigenetic mechanisms with the help of analytic and synthetic methods and identify the proteins involved. This way, the way for new options for the therapy of diseases such as cancer and certain mental disorders is to be opened up and paved.

TU München